Bragar Eagel & Squire, P.C. Is Investigating Quanterix and TransMedics and Encourages Investors to Contact the Firm

Quanterix Corporation (NASDAQ:QTRX) - Quanterix disclosed an error in the capitalization of labor and overhead costs for prior periods, affecting inventory valuation, and advised that the financial statements containing these errors should no longer be considered reliable [2] - Following the announcement, Quanterix's stock price fell by 18.3%, closing at $12.40 per share on November 13, 2024 [3] TransMedics Group, Inc. (NASDAQ:TMDX) - The investigation into TransMedics focuses on whether the company issued false or misleading statements and failed to disclose pertinent information to investors [3] - A report by Scorpion Capital described TransMedics as the most extreme healthcare fraud encountered in 20 years, claiming it exploits terminally ill patients desperate for organ transplants [3]